Table 4.
Specimens, diagnostic method and reported but unverified antibiotic susceptibility test results in 42 culture-confirmed melioidosis cases with available clinical data from 2012 to 2017.
| Characteristics | Total (n = 42) |
|---|---|
| Specimens * | |
| Blood | 25 (60%) |
| Pus | 8 (19%) |
| Urine | 7 (17%) |
| Tissue ** | 2 (5%) |
| Sputum | 1 (2%) |
| Diagnostic method | |
| Vitek 2 identification system | 37 (88%) |
| Microgen | 5 (12%) |
| Antibiotic susceptibility test | |
| Not done | 27 (64%) |
| Done *** | |
| Gentamicin (S) | 0/13 (0%) |
| Amoxicillin-clavulanic acid (S) | 2/5 (40%) |
| Ceftazidime (S) | 12/14 (86%) |
| Doxycycline (S) | 7/9 (78%) |
| Meropenem (S) | 14/15 (93%) |
| Imipenem (S) | 2/2 (100%) |
| Trimethoprim-sulfamethoxazole (S) | 6/7 (86%) |
* One adult patient had two culture-positive specimens. ** Tibial tissue (1), scrotal tissue (1). *** Data are number of isolates demonstrating susceptibility to the antimicrobial over the total number of isolates tested (%). Data are from the microbiology laboratories that had isolated B. pseudomallei from clinical specimens. Some AST results were not typical for B. pseudomallei, including resistance to amoxicillin-clavulanic acid, ceftazidime, doxycycline, meropenem and trimethoprim-sulfamethoxazole. We note that the AST results may be inaccurate or some isolates might not actually be B. pseudomallei.